Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23613007 | 0.79 | ALDH1A1 (0.43) | CNR2ALDH1A1CYP2C9HPGDCYP2C19 | |
| SCHEMBL23547248 | 0.79 | CNR2 (0.34) | CNR2KDM4EALDH1A1GAACYP2C9 | |
| SCHEMBL5814918 | 0.74 | ACACB (0.34) | ACACBCNR2KDM4EALDH1A1CYP2C9 | |
| SCHEMBL21100818 | 0.74 | ACACB (0.34) | ACACBCNR2KDM4EALDH1A1CYP2C9 | |
| SCHEMBL21361192 | 0.74 | ACACB (0.34) | ACACBCNR2KDM4EALDH1A1CYP2C9 | |
| SCHEMBL8847890 | 0.74 | ALDH1A1 (0.46) | ACACBCNR2ALDH1A1HPGDTAS1R3 | |
| SCHEMBL19699581 | 0.74 | MMP1 (0.48) | CNR2KDM4EALDH1A1GAANPSR1 | |
| SCHEMBL14707759 | 0.74 | ASAH1 (0.38) | CNR2ALDH1A1NPSR1 | |
| SCHEMBL13887653 | 0.74 | ASAH1 (0.38) | CNR2ALDH1A1NPSR1 | |
| SCHEMBL19699582 | 0.74 | MMP1 (0.48) | CNR2KDM4EALDH1A1GAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | SHBG, CYP19A1, GNRHR | ACACB 2418/4885CNR2 94/4885KDM4E 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.